

## Article (refereed) - postprint

---

Johnson, Andrew C.; Juergens, Monika D.; Nakada, Norihide; Hanamoto, Seiya; Singer, Andrew C.; Tanaka, Hiroaki. 2017. **Linking changes in antibiotic effluent concentrations to flow, removal and consumption in four different UK sewage treatment plants over four years.**

© 2016 Elsevier Ltd.

This manuscript version is made available under the CC-BY-NC-ND 4.0 license <http://creativecommons.org/licenses/by-nc-nd/4.0/>



This version available <http://nora.nerc.ac.uk/515653/>

NERC has developed NORA to enable users to access research outputs wholly or partially funded by NERC. Copyright and other rights for material on this site are retained by the rights owners. Users should read the terms and conditions of use of this material at <http://nora.nerc.ac.uk/policies.html#access>

NOTICE: this is the author's version of a work that was accepted for publication in *Environmental Pollution*. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in *Environmental Pollution* (2017), 220 (B). 919-926. [10.1016/j.envpol.2016.10.077](https://doi.org/10.1016/j.envpol.2016.10.077)

[www.elsevier.com/](http://www.elsevier.com/)

Contact CEH NORA team at  
[noraceh@ceh.ac.uk](mailto:noraceh@ceh.ac.uk)

1 **Linking changes in antibiotic effluent concentrations to flow, removal**  
2 **and consumption in four different UK sewage treatment plants over four**  
3 **years**

4 Andrew C. Johnson\*<sup>1</sup>, Monika D. Jürgens<sup>1</sup>, Norihide Nakada<sup>2</sup>, Seiya Hanamoto<sup>2</sup>, Andrew C. Singer<sup>1</sup>, Hiroaki  
5 Tanaka<sup>2</sup>

6 \*Corresponding author, email [gjo@ceh.ac.uk](mailto:gjo@ceh.ac.uk)

7 <sup>1</sup>NERC Centre for Ecology and Hydrology, Wallingford, Oxfordshire, OX10 8BB, United Kingdom

8 <sup>2</sup>Research Centre for Environmental Quality Management, Kyoto University, 1-2 Yumihama, Otsu, Shiga 520-  
9 0811, Japan

10

11

12 **Abstract**

13 *The arrival and discharge of seven antibiotics were monitored at two trickling filter sewage*  
14 *treatment plants of 6,000 and 11,000 population equivalents (PE) and two activated sludge plants*  
15 *of 33,000 and 162,000 PE in Southern England. The investigation consisted of 24 h composite*  
16 *samples taken on two separate days every summer from 2012 to 2015 and in the winter of 2015*  
17 *(January) from influent and effluent. The average influent concentrations generally matched*  
18 *predictions based on England-wide prescription data for trimethoprim, sulfamethoxazole,*  
19 *azithromycin, oxytetracycline and levofloxacin (within 3-fold), but were 3-10 times less for*  
20 *clarithromycin, whilst tetracycline influent concentrations were 5-17 times greater than expected.*  
21 *Over the four years, effluent concentrations at a single sewage plant varied by up to 16-fold for*  
22 *clarithromycin, 10-fold for levofloxacin and sulfamethoxazole, 7-fold for oxytetracycline, 6-fold for*  
23 *tetracycline, 4-fold for azithromycin and 3-fold for trimethoprim. The study attempted to identify*  
24 *the principal reasons for this variation in effluent concentration. By measuring carbamazepine and*  
25 *using it as a conservative indicator of transport through the treatment process, it was found that*  
26 *flow and hence concentration could alter by up to 5-fold. Measuring influent and effluent*  
27 *concentrations allowed assessments to be made of removal efficiency. In the two activated sludge*  
28 *plants, antibiotic removal rates were similar for the tested antibiotics but could vary by several-fold*  
29 *at the trickling filter plants. However, for clarithromycin and levofloxacin the variations in effluent*  
30 *concentration were above that which could be explained by either flow and/or removal alone so*  
31 *here year on year changes in consumption are likely to have played a role.*

32 .

33 **Highlights**

- 34 • Concentrations of 7 antibiotics were measured in 4 sewage treatment plants (STPs)
- 35 • Prescription data was used to predict concentrations in influent and effluent
- 36 • Measured concentrations and removal rates in STPs were very variable
- 37 • Average measured values were in line with predictions for 5 of 7 antibiotics
- 38 • Changes in flow, removal rates and consumption influenced effluent levels

39 **Capsule**

40 Considerable variation in effluent concentration for 7 antibiotics in 4 sewage treatment plants over  
41 4 years was observed. This variation was driven by changes in wastewater flow, removal rates and  
42 local drug consumption

43 **Keywords**

44 antibiotics  
45 sulfamethoxazole  
46 clarithromycin  
47 trimethoprim  
48 tetracycline  
49 effluent

51 **Abbreviations**

52 TRIM – trimethoprim, SMX – sulfamethoxazole, CBZ – Carbamazepine, CLAR – clarithromycin, AZO –  
53 azithromycin, TET – tetracycline, OXY – oxytetracycline, LEVO – levofloxacin, STP – sewage treatment plant,  
54 AS – activated sludge, TF – trickling filter

56 **1. Introduction**

57 Prioritisation exercises for pharmaceuticals in the environment typically list antibiotics as  
58 one of the groups of highest concern (Besse and Garric, 2008; Christensen et al., 2009; Cooper et  
59 al., 2008). Their high ranking is linked not only to their high levels of consumption and toxicity to  
60 aquatic wildlife but also to concerns over possible links to antibiotic resistance which could have  
61 consequences for mankind (Ågerstrand et al., 2015). This was prompted by the co-occurrence of  
62 antibiotics and antibiotic resistance genes in some river environments (Amos et al., 2015; Huerta et  
63 al., 2013; Marti et al., 2013; Marti et al., 2014; Rodriguez-Mozaz et al., 2015). Geographic based  
64 modelling has been used as part of the risk assessment process for antibiotics (Johnson et al., 2015;  
65 Singer et al., 2014). If we should wish to remove more antibiotics in sewage treatment, it will be

66 important to identify the factors associated with good performance. Currently this is difficult due  
67 to the surprisingly wide variety in effluent concentrations and apparent removal rates of similar  
68 antibiotics found in the literature.

69 There have been a number of studies which have examined temporal changes in antibiotic  
70 loadings in sewage treatment plants (STPs) ranging from daily (Coutu et al., 2013; Singer et al.,  
71 2014) to seasonal (Gracia-Lor et al., 2012). Probably the most notable observation has been a  
72 seasonal increase in consumption for some antibiotics associated with winter. For example, in the  
73 Czech Republic and Switzerland, both clarithromycin and trimethoprim consumption doubled in  
74 winter (Coutu et al., 2013; Golovko et al., 2014; McArdell et al., 2003). For sulfamethoxazole,  
75 concentrations in influent rose by one-quarter to one-third in winter in the Czech Republic, Greece  
76 and China (Golovko et al., 2014; Kosma et al., 2014; Zhang et al., 2015), but in Portugal  
77 consumption was higher in spring than summer for the two antibiotics studied (azithromycin and  
78 ciprofloxacin) (Pereira et al., 2015). Sometimes the observed loadings (consumption) appear to be  
79 a lot higher than might have been expected from reviewing national or regional prescription data  
80 (Singer et al., 2014).

81 There have not been many studies reviewing the performance of different sewage  
82 treatment types with respect to antibiotics, but in a Chinese study a membrane bioreactor gave  
83 better removal performance for trimethoprim than a conventional activated sludge (AS) plant (Sui  
84 et al., 2011). In the UK there did not appear to be a consistent trend in performance between  
85 activated sludge plants or trickling filters with respect to oxytetracycline removal (Gardner et al.,  
86 2013).

87 Regarding seasonal changes in sewage treatment removal performance, for the Czech  
88 Republic it appeared that clarithromycin and trimethoprim removal improved by 20% in summer  
89 compared to winter, whilst levofloxacin and sulfamethoxazole improved by 10% (Golovko et al.,  
90 2014). In a Chinese study, trimethoprim removal performance improved from 30 to 80% in the  
91 Beijing summer, which might have been temperature related (Sui et al., 2011). In Portugal, higher  
92 azithromycin and ciprofloxacin removal was reported in summer compared to spring (80% versus  
93 50%).

94 These studies imply consumption for some antibiotics could increase between two and four-  
95 fold in winter and removal performance decline by more than 2/3. However, this may not always  
96 lead to higher antibiotic concentrations in the river. Many Western countries experience their

97 highest river flows in winter, so that dilution might rise 30-fold (Johnson, 2010) which more than  
98 compensates for relatively minor changes in seasonal antibiotic use or removal efficiency.

99 Changes in effluent concentrations of antibiotics over several years at the same STP has not  
100 been examined before. Nor have there been serious attempts to disentangle the reasons for  
101 variations in effluent concentrations over long time-scales. A better understanding of why there  
102 are differences in antibiotic discharge between STPs would assist both risk assessment and a  
103 strategy to improve their removal from wastewater.

104 Following the development of a method, which permitted the simultaneous analysis of  
105 several pharmaceuticals in wastewater including some key antibiotics, a study was prepared to look  
106 at several antibiotics in use in the UK. Sulfamethoxazole (SMX) is used to treat infections such as  
107 urinary tract, inner ear, proctitis and bronchitis. It is one of the sulphonamide group which entered  
108 the market in the 1970s and inhibits an enzyme involved in the synthesis of tetrahydrofolic acid  
109 (part of the thymidine metabolic pathway in DNA synthesis) (Seydel et al., 1972). Trimethoprim  
110 (TRIM) is used to treat a number of infections including those of the urinary and respiratory tract  
111 and belongs to the class of chemotherapeutic agents known as dihydrofolate reductase inhibitors.  
112 TRIM acts by targeting an enzyme involved in the tetrahydrofolic acid pathway and so SMX and  
113 TRIM have often been used together in therapy since the late 1960s (Burchall, 1973; Seydel et al.,  
114 1972). Clarithromycin (CLAR) is used to treat infections such as skin, throat and pneumonia.  
115 Azithromycin (AZO) has been used to treat throat, intestinal and sexually transmitted infections.  
116 Both of these are macrolide antibiotics which came on the market in the early 1990s and bind to  
117 the microbial 50s ribosome sub-unit thereby inhibiting protein synthesis (Piscitelli et al., 1992;  
118 Retsema et al., 1987). Tetracycline (TET) is often used in treating skin infections and Lyme disease  
119 whilst oxytetracycline (OXY) has been used to treat skin, chest and genital infections. These two  
120 antibiotics have been in use since the 1960s and target the microbial 30s ribosomal sub-unit to  
121 inhibit protein synthesis (Gale, 1963). Levofloxacin (LEVO) has been used to treat a range of  
122 infections including intestinal, pneumonia, urinary tract and proctitis. It belongs to the  
123 fluoroquinolone group of antibiotics, which became widely used from 1990, and function by  
124 inhibiting the DNA gyrase and topoisomerase IV enzymes (Drlica and Zhao, 1997; Hooper et al.,  
125 1987).

126 By looking at 4 different sewage treatment plants over 4 years, sampling on two occasions each  
127 year through taking 24 h composite samples, this study attempted to address the following  
128 questions:

129 How variable are antibiotic effluent concentrations over four years within four different UK  
130 sewage treatment plants? To what extent are antibiotic influent and effluent concentrations  
131 predictable based on National consumption rates? To what extent does sewage treatment type  
132 influence removal performance? How important are flow, removal performance or changes in  
133 drug consumption in the variability of antibiotic effluent concentrations?  
134

134

## 135 2. Materials and methods

### 136 2.1. *Sampling approach at the treatment plants and flow assessment*

137 Four separate STPs in Southern England, UK were examined (Table 1). Two plants were of  
138 the activated sludge (AS) type (Ox and Did) and two smaller plants of the trickling filter (TF) type  
139 (Ben and Cho). In the UK, AS plants have a hydraulic residence time in the region of 10-14 h and TF  
140 plants only 0.5 h. The AS plants handle the most wastewater but TFs are the most numerous  
141 (Johnson et al., 2007). A 24 hr composite sample was collected by combining hourly samples using  
142 an autosampler (Isco Avalanche, Isco 6712, Hach Sigma SD 900 or Bühler Montec Xian 1000). Each  
143 treatment plant was sampled, using composite samplers, on two separate occasions during each  
144 sampling campaign in June 2012, August 2013, August 2014 and January and August 2015. There  
145 have been issues with insufficient or inappropriate sample frequency leading to a number of  
146 misinterpretations in understanding the fate of pharmaceuticals in treatment plants (Ort et al.,  
147 2010). One example is that in periods of high rainfall both rainwater and elevated groundwater can  
148 enter the sewer system, which could have the effect of greatly diluting concentrations of chemicals  
149 derived from local households. However, these sampling periods did not occur during periods of  
150 high rainfall in the region (Table S1). In addition, this study used carbamazepine as a form of  
151 conservative tracer to help avoid misinterpretations of the relative influence of flow versus other  
152 losses as described further below.

153

154 **Table 1 Sewage treatment plants sampled in the survey**

Type	Tertiary treatment	Name	Human PE (k)	Ave. dry weather flow (m <sup>3</sup> /d)	L/person
AS	None	Ox	162.8	38,000	233
AS	Sand filter	Did	31.7	8,000	252
TF	Particle filter	Cho	11.3	2,406	213
TF	Nitrifying Fixed bed bioreactor & Particle filter	Ben	5.9	1,368	232

155  
 156 AS Activated Sludge  
 157 TF Biological filter (trickling filter)  
 158 Human PE human population equivalent = head of population connected to the sewage plant  
 159 Values from the database for the LF2000WQX model (Williams et al., 2009)  
 160

161 Unfortunately, daily flow values at the STPs were not available, only the consented flow  
 162 (Table 1). In the UK, sewage treatment is managed by private companies and there is no  
 163 requirement to make such information publically available. However, the conservative  
 164 pharmaceutical carbamazepine (CBZ) makes a very suitable indicator for changes in flow. It is very  
 165 widely prescribed for epilepsy patients, who take this medication at the same dose throughout the  
 166 year, and its remarkable persistence has been noted before (Clara et al., 2004; Nakada et al., 2008).  
 167 Measurements taken in this study showed no decline between the influent and effluent (Tables S4  
 168 and S6).

## 170 2.2 Analytical approach

171 The method of pharmaceutical analysis described elsewhere (Narumiya et al., 2013) was  
 172 used with minor modifications. Briefly, water samples were taken in polyethylene bottles or  
 173 buckets, to which 1 g/L ascorbic acid had been added as a preservative. Immediately after being  
 174 taken, the samples were filtered through glass fibre filters (GF/B, 1.0 µm, Whatman, UK) and EDTA  
 175 (to be approximately 1 g/L) and a 50 µL of surrogate mixture (1 mg/L of each isotope-labelled  
 176 pharmaceutical dissolved in methanol) were added into the filtrate. The antibiotics were  
 177 concentrated by solid-phase extraction in an OASIS HLB cartridge (200 mg, 6 cm<sup>3</sup>, Waters, MA)  
 178 within 1 d after sampling. The cartridges were kept at 4 °C in darkness and transported to Kyoto  
 179 University, Japan, where the compounds retained in the cartridge were eluted with 6mL of  
 180 methanol after being dried for 1 h under gentle air pressure in a glass manifold. The eluents were

181 dried with nitrogen gas and dissolved in 1 mL of 0.1% formic acid and methanol (85:15, v/v). The  
182 antibiotics were measured by ultra-performance liquid chromatography–tandem mass  
183 spectrometry (LC–MS/MS) and the values quantified were correlated with the recovery rate of the  
184 surrogate (Narumiya et al., 2013). Antibiotic concentrations were reported after a three-tiered  
185 assessment (Kuroda et al., 2015) as follows. First, the concentration in the sample in the injection  
186 vial had to be more than three times higher than that in the running blank for each sampling day;  
187 otherwise, the concentration was reported as below the limit of quantification (<LOQ). Second, the  
188 signal to noise ratio (S/N) had to be more than 10; otherwise, the concentration was also reported  
189 as <LOQ. Finally, the recovery of surrogate compounds had to be more than 30%; otherwise, the  
190 concentration was reported as LR (low recovery). For running blank samples, 100 - 500 mL of  
191 ultrapure water (Milli-Q waters) was analysed in each week during the sampling period. The LOQ  
192 was set at the larger value of either three times of the running blank concentration or the sample  
193 concentration with a signal to noise ratio of 10.

194

### 195 *2.3 Predicting antibiotic per capita consumption, influent and effluent concentrations*

196

197 It is possible to access English data on prescriptions from the Health and Social Care  
198 Information website for pharmaceutical consumption  
199 <http://www.hscic.gov.uk/searchcatalogue?productid=17711>. In theory, this data should be a  
200 reasonable guide, since in the UK antibiotics are only obtained by prescription from a medical  
201 practice. This can be used to calculate per capita consumption using the population data for that  
202 year obtained from the Office for National statistics [http://www.ons.gov.uk/ons/rel/pop-  
203 estimate/population-estimates-for-uk--england-and-wales--scotland-and-northern-ireland/2013/index.html](http://www.ons.gov.uk/ons/rel/pop-estimate/population-estimates-for-uk--england-and-wales--scotland-and-northern-ireland/2013/index.html)  
204 To predict influent concentrations, the amount of intact parent compound excreted by patients  
205 needs to be found from the medical literature. This will have some limitations as it is not always  
206 clear whether a study refers to a conjugated or free compound, and faecal excretion is often not  
207 reported. In this study a mean as well as highest and lowest excretion value was recorded (Table  
208 S2). From this, a probable influent concentration range can be predicted using the mean  
209 wastewater discharge per capita of 233 L/d for these STPs (Table 1). Removal rates for sewage



210 treatment can also be compiled from the literature and are reported as a weighted mean, highest  
211 and lowest removal (Table S3).

212 To summarise, the influent concentrations are predicted by taking the drug consumption per capita  
213 for a nation less that prevented from being excreted as the free parent compound. For the effluent  
214 concentration the value is modified by that removed in sewage treatment. So, for example, the  
215 effluent concentration ( $W$ , in ng/L) is derived as follows:

$$216 \quad W = \frac{(C \times E \times (1-R))}{D}$$

217 Where  $C$  is the substance consumption (ng/cap/d);  $E$  is the substance amount not excreted  
218 (ng/cap/d);  $R$  is the amount of the drug that is prevented from escaping into sewage effluent  
219 (ng/cap/d); and  $D$  is the volume of wastewater ( L/cap/d).

220 The mean excretion and mean sewage removal rate can be combined to report the  
221 expected effluent concentration, whilst the lowest excretion rate and highest sewage removal rate  
222 predict the best possible effluent concentration and finally, the highest excretion rate and lowest  
223 sewage removal rate predict the worst possible effluent concentration.

224

### 225 **3. Results and discussion**

226

227 In this discussion of the results, it is important to distinguish between observations of  
228 effluent concentration, which is about exposure, and an explanation of the factors which might be  
229 driving that variation in effluent concentration. Recording the differences in effluent concentration  
230 has a value in its own right since it is important to assess and predict environmental exposure as  
231 accurately as we can. Exposure models need corroboration with measured data. Then there is the  
232 issue of trying to identify the principal cause behind that variability. There are three major  
233 candidates to explain the variability in effluent exposure, these are; that changes in flow (dilution)  
234 is the driving variable in the STP, that the quantity of drugs arriving at the STP is changing (human  
235 consumption), or that removal within the STP is fluctuating. As tools to examine why there are

236 differences in effluent concentration, we can compare with the influent concentration (to give an  
237 indication of removal) and with a conservative indicator to tell us about changes in flow.  
238 Carbamazepine (CBZ) is a suitable conservative indicator, because the molecule is very resistant to  
239 degradation and as an epilepsy drug it is consumed at constant rates throughout the year (Clara et  
240 al., 2004; Nakada et al., 2008).

241

### 242 *3.1 Comparison of measured antibiotic concentrations with those predicted by national* 243 *consumption*

244

245 A fundamental part of predicting antibiotic concentrations in sewage is the use of national  
246 consumption statistics followed by an assessment of patient excretion. In this study, this approach  
247 gave acceptable predictions for most antibiotics (Table 2). However, assuming the excretion values  
248 were not erroneous (Table S2), this region appears to consume significantly less CLAR and more TET  
249 than expected for England as a whole.

**Table 2. Consumption, predicted influent and effluent concentrations of the selected antibiotics together with measured influent and effluent concentrations. Numbers in parentheses are highest and lowest expected, or highest and lowest measured.**

	TRIM	SMX	CLAR	AZO	TET	OXY	LEVO
<b>Influent</b>							
2014 National use (kg/yr)	11,599	2,255	18,796	2,579	903	16,473	116
Individual (mg/cap/d)	0.590	0.115	0.955	0.131	0.046	0.837	0.006
Expected (ng/L) <sup>a</sup>	1163 (1087-1517)	89 (49-148)	2049 (1517-2459)	225 (67-264)	118 (128-138)	1796 (1078-2515)	21 (17-24)
Measured Ox (ng/L)	733 (574-1022)	230 (128-356)	533 (247-773)	368 (214-507)	1660 <sup>c</sup>	827 <sup>c</sup>	28 (<LOQ-56)
Measured Did (ng/L)	575 (313-939)	138 (29-244)	454 (331-579)	207 (77-292)	1887 (747-3028)	1099 (598-1600)	22 (<LOQ-79)
Measured Cho (ng/L)	588 (202-1582)	163 (62-318)	421 (123-641)	222 (105-359)	1166 (845-1486)	492 (112-872)	1.8 <sup>d</sup> (<LOQ 11)
Measured Ben (ng/L)	327 (88-529)	32 (11-53)	184 (<LOQ-497)	150 (108-213)	564 <sup>c</sup>	1406 <sup>c</sup>	40 (<LOQ -119)
<b>Comment on influents</b>	1.6-3.6 x less than expected ≈as expected	≈as expected	3.8-11 x less than expected, perhaps due to low consumption	≈as expected	4.8-16x more than expected	1.3-3.6 x less than expected ≈as expected	≈as expected
<b>Effluent</b>							
Expected (ng/L) <sup>b</sup>	885 (338-1504)	46 (12-147)	1517 (136-2435)	164 (30-264)	54 (1.2-131)	395 (97-1886)	11 (4.3-18)
Measured Ox (ng/L)	359 (294-455)	88 (59-141)	98 (24-377)	156 (69-264)	45 (25-84)	32 (17-40)	5.3 (<LOQ-16)
Measured Did (ng/L)	243 (160-305)	92 (24-140)	104 (40-221)	110 (74-215)	119 (77-173)	84 (43-144)	5.9 (<LOQ-11)
Measured Cho (ng/L)	208 (128-321)	128 (61-227)	181 (92-338)	91 (48-135)	98 (58-174)	56 (21-146)	2.1 (<LOQ-4.5)
Measured Ben (ng/L)	161 (87-254)	27 (<LOQ-55)	152 (64-334)	76 (35-133)	133 (42-239)	191 (99-602)	11 (<LOQ-47)
<b>Comment on effluents</b>	2.5-5.5 x less than expected, mainly due to low influent conc.	Variable, but ≈as expected	8.4-16 x less than expected mainly due to low influent conc.	≈as predicted	Variation between STPs but closer to expectation than influent	Less than expected, high variation between STPs	≈as expected

<sup>a</sup> Calculated with local wastewater discharge of 233 L/cap/d and range of excretion proportions [weighted average (min-max)] given in table S1

<sup>b</sup> Calculated with STP removal rates given in table S2: expected value=average excretion with average removal, range=best case (lowest excretion with highest removal) to worst case (highest excretion with lowest removal)

<sup>c</sup> Only one valid measurement

<sup>d</sup> Very uncertain average, because 5 of 6 values were <LOQ (set to 0 for the calculation)

250 *3.2 Variation in carbamazepine concentrations and the relationship to STP flow*


251 In the absence of metered flow values for the STPs, changes in CBZ concentration were used  
252 as an indicative marker of changes of flow within the sewage treatment system. To serve as a  
253 useful conservative marker it should be readily detectable at all the plants at similar concentrations  
254 proportional to the human population. This also assumes that a high proportion of the population  
255 consistently consumes and excretes the drug. In fact, the measurements were broadly similar at all  
256 sites with an influent summer average of 613 ng/L of CBZ. The compound also did demonstrate a  
257 conservative nature as the effluent concentration was between 94 and 144% of the influent  
258 concentration across the different STPs over the 4 years. The variation over all years sampled in the  
259 influent CBZ concentration was 2-3 fold at Ox and Ben with 4-fold at Did and 5-fold at Cho. Thus,  
260 up to a 5-fold variation in influent antibiotic concentration over all years sampled at a STP could be  
261 considered 'natural' and potentially linked to flow. It was noticeable that the January CBZ  
262 concentration was half that of the summer average. This would be consistent with a doubling of  
263 sewer flow associated with an ingress of rain or groundwater into the system in winter.

264

265 *3.3 Variation in antibiotic influent and effluent concentrations*

266 Measurements in the influent proved somewhat challenging with some recovery problems  
267 in this matrix (Table S4), thus the averages shown in figure 1 are sometimes from a smaller number  
268 of successful measurements. Typically, influent concentrations for these different antibiotics can  
269 double (or halve) depending on the year (Table S5) but the differences can be quite large for some,  
270 such as 8-fold for OXY and TRIM at Cho compared to only 5-fold for CBZ at this plant. Similarly, an  
271 8-fold variation in influent concentrations of SMX were observed at Did over 3 years compared to a  
272 4-fold variation in CBZ. This compares with a 3-5-fold seasonal variation in antibiotic loading over  
273 the course of one year at a Swiss STP (Coutu et al., 2013).

274



275


276 Figure 1. Antibiotic and carbamazepine influent concentrations (mean and SD) at the different plants over  
 277 four years. Note for each STP the number of available influent values were for TRIM n=6-10, for SMX n=7-  
 278 10, for CLAR n=5-7, for AZO n=4-6, for TET n=1-2, for OXY n=1-2, for LEVO n=1-5 and for CBZ n=5-10 (full  
 279 details in Table S4).

280

281 It was planned to take two separate composite samples for both influent and effluent at  
 282 each STP a few days apart. However, autosamplers failed on some occasions whilst on others the  
 283 recovery was too low (less than 30%) and so the measurement was not included. The biggest  
 284 problems with recovery were for TET and OXY. But, for most years, at each location, the results  
 285 were from two measurements taken on separate days (Table S4).

286 Over the four years of sampling, effluent concentrations at an STP could vary by up to 16-  
 287 fold for CLAR, 10-fold for SMX and LEVO, 7-fold for OXY, 6-fold for TET, 4-fold for AZO and 3-fold for  
 288 TRIM (Table S5). In comparison the effluent concentration of the conservative pharmaceutical CBZ  
 289 varied by no more than 4-fold at any STP (Table S5). For most antibiotics the highest relative  
 290 variability in effluent concentrations were found at the smallest works, the trickling filter plant at  
 291 Ben (6000 PE) (Fig. 2).

292



293


294 Figure 2. Antibiotic and carbamazepine effluent concentrations (mean and SD) at the different plants over  
 295 four years. Note for each STP the number of available effluent values were for TRIM n=6-10, for SMX n=5-9,  
 296 for CLAR n=5-10, for AZO n=5-9, for TET n=3-8, for OXY n=3-8, for LEVO n=3-6 and for CBZ n=5-10 (full details  
 297 in Table S4).

298

299 *3.4 The role played by changes in STP flow on antibiotic concentrations*

300

301 The anti-epileptic pharmaceutical CBZ was selected as a conservative indicator and thus  
 302 reveal the impact of changes in wastewater flow entering the treatment plants. Thus, an increase  
 303 in CBZ concentration was interpreted as a reduction in the quantity of wastewater in the sewer (i.e.  
 304 reduced dilution) whilst a big reduction of CBZ concentration would most likely reflect an ingress of  
 305 rain or groundwater causing dilution in the system. As an example, for the biggest STP, Ox, it will  
 306 be noted that a 26% drop in CBZ concentration which occurred in January 2015 was mirrored by  
 307 most antibiotics where we have data (Fig. 3). A 1/3 increase in CBZ concentration in August 2015  
 308 was not matched by SMX or CLAR. Indeed the ratio of CLAR to CBZ is unstable indicating changes in  
 309 prescription/use is most likely driving the variability in influent concentration for this antibiotic.



310

311 Figure 3. Comparison of some antibiotic influent concentrations (ng/l) against carbamazepine (CBZ) over  
 312 four years (All data is plotted and the line is the average).

313

### 314 3.5. Variation in antibiotic removal performance of STPs


315 The AS pair of Ox and Did were not consistently better than the TF pair of Cho and Ben at  
 316 removing antibiotics from the waste stream (Fig 4, Table S6), but performed on average better than  
 317 the trickling filter types for two (CLAR and SMX) of the four antibiotics for which sufficient data  
 318 were available for a robust comparison. The mean removals of CLAR and SMX were 79% (SD 18%)  
 319 and 40% (SD 22%) respectively for the combined AS plants compared to 36% (SD 26%) and 15% (SD  
 320 40%) for the two TFs (Table S6). For TRIM there was little difference in removals between the ASPs

321 (47% (SD 15%) compared to 44% (SD 25%) at the TFs. For AZO at the ASPs 34% (SD 21%) was  
322 removed compared to 42% (SD 31%) at the TFs. For the remaining antibiotics LEVO, OXY and TET  
323 only 1-3 valid pairs of influent and effluent concentrations were available for each pair of sewage  
324 works making any comparisons unreliable. A previous study of the removal of trickling filter plants  
325 reported only 3 to -23% removal for SMX and 40% removal for TRIM (Kasprzyk-Hordern et al.,  
326 2009). The winter period of January 2015 did not produce noticeably worse antibiotic removal  
327 performance than the summer samplings.

328 Both of the TFs (Ben and Cho) showed considerable variation in antibiotic removal  
329 performance from year to year (Fig. 4). Occasionally, a higher antibiotic concentration was found in  
330 the effluent than influent of those TF plants (TRIM in 2013 in Cho and LEVO in 2012 and SMX in  
331 summer 2015 in Ben). Analysing 24-hour composite samples reduces the effects of short term  
332 variations compared to grab-samples, but temporal changes in the influent concentrations could  
333 still lead to a certain level of sample mis-match, especially if an unusually high influent  
334 concentration preceded the initiation of sampling or a high load was just about to leave in the  
335 effluent. It is also possible that higher than expected effluent concentrations were due to the  
336 delayed release of the parent molecule from a conjugate without further significant removal. Good  
337 performance in removal of one antibiotic in one year did not necessarily translate to good removal  
338 for another antibiotic. In other words performance was quite unpredictable in all senses for these  
339 TF plants.

340 In contrast, the AS plant Ox showed remarkable removal consistency for all antibiotics in  
341 each year with the exception of TRIM in summer 2012 and CLAR in winter 2015 (Fig. 4). The highest  
342 removals (84-97%) were for TET and OXY.





x calculated from concentrations + calculated relative to CBZ

344 Figure 4. Differences in removal performance of antibiotics at the different treatment plants over four  
345 years. Results were calculated from valid duplicate or single paired 24 h composite influent and effluent  
346 samples. AS: activated sludge process, TF: trickling filter.

347

348

### 349 *3.6 Attempting to attribute variation in effluent antibiotic concentration*

350

351 As discussed previously, we may attribute variability in antibiotic effluent concentration to  
352 to changes in wastewater dilution, differences in removal rates (treatment), or to changes in drug  
353 consumption. Changes in drug consumption rates may be inferred if variability in dilution or STP  
354 removal are insufficient to account for changes in effluent concentration. Changes in flow within  
355 the STP are assessed by differences in CBZ and could account for some of the variation in every  
356 case. This was particularly notable as higher flows in January 2015 and lower than usual flows in  
357 August 2015. Secondly there is the inconsistency in the efficiency of sewage treatment (removal)  
358 most notably in the trickling filter plant Ben (Table 3). Where neither of these two factors are  
359 sufficient to explain the variability in effluent concentrations, a change in the local drug  
360 consumption may be inferred. Thanks to its greater stability of performance and flow at the largest  
361 STP studied (Ox) it is possible to attribute differences in CLAR and LEVO effluent concentrations  
362 there largely to changes in local drug consumption. For CLAR the influent concentrations during the  
363 winter sampling were higher than expected compared to CBZ (fig. 3) at all four STPs making it  
364 likely that increased prescription in winter played a role here. Similarly, much of the changes in  
365 LEVO at Ben may be attributable to consumption changes. Ben is the smallest STP studied and LEVO  
366 the rarest drug, meaning that if there are only a few people taking it at any one time, so variability  
367 can be introduced just by a single person starting or stopping taking it. However, the influence of  
368 sewage treatment performance for this antibiotic cannot be ruled out because there is insufficient  
369 data to quantify the performance and its variability (fig. 4 and table S6).

370

371 **Table 3. Analysis of the largest recorded incidences of variation in antibiotic effluent**  
 372 **concentration**

373

STP	Antibiotic	Change in effluent concentration	Change in carbamazepine dilution marker in effluent	STP removal performance	Likely attribution of variability
Ox	CLAR	16-fold	2-fold	50-95% (2-fold)	Largely consumption changes
	LEVO	5-fold		Consistent 75%	Largely consumption changes
Did	CLAR	5-fold	4-fold	50-75% (1.5-fold)	Instability in flow and removal
	SMX	6-fold		0-30% (several-fold)	Instability in flow and removal
Cho	OXY	7-fold	5-fold	Variability unknown	Changes in flow plus unknown
Ben	CLAR	5-fold	4-fold	5-25% (5-fold)	Instability in flow and removal
	SMX	10-fold		20-50% (2.5-fold)	Changes in local flow, removal and consumption combined
	LEVO	10-fold		0%	Largely a consumption issue with a smaller influence of changes in local flow
	OXY	6-fold		Variability unknown	Changes in flow plus unknown
	TET	6-fold		Variability unknown	Changes in flow plus unknown

374

375

#### 376 **4. Conclusions**

377 The average influent concentrations of the four sewage plants fell within a maximum factor  
 378 of 4 of average predictions based on England-wide prescription data for SMX, TRIM, AZO, OXY, and  
 379 LEVO but were 4-11 times less for CLAR whilst TET influent concentrations were 5-16 times greater  
 380 than expected. For the two trickling filter plants, removal rates were very variable both year on  
 381 year and without consistency between antibiotics. The large activated sludge plant (Ox) showed  
 382 more consistent removal and better performance than the other plants for CLAR and SMX. Over  
 383 the four years, sewage effluent concentrations varied up to 16-fold CLAR, 10-fold for LEVO and  
 384 SMX, 7-fold for oxytetracycline OXY, 6-fold for TET, 4-fold for AZO and 3-fold for TRIM.

385 Changes in flow and removal performance within the STPs were clearly playing an important  
386 role in this variability of effluent concentration. However, these were not sufficient to account for  
387 all the variability in some cases for CLAR and LEVO and here year on year and seasonal changes in  
388 prescriptions and regional prescription preferences are likely to have played a role.

389

## 390 **Acknowledgements**

391 The authors are grateful to the Defra and Japanese Ministry of the Environment supported  
392 UK/J cooperation, the CEH Science budget provided by NERC and Japan Society for the Promotion  
393 of Science (JSPS) Grant-in-Aid for Scientific Research (A) (Number 25257304, 23254003 and  
394 26257302). We would like to thank Dr. Masaru Ihara, Dr. Vimal Kumar, and several graduates and  
395 undergraduates of RCEQM, Kyoto University for their assistance in the laboratory and fieldwork.

396

## 397 **References**

398

- 399 Ågerstrand, M., Berg, C., Bjorlenius, B., Breitholtz, M., Brunstrom, B., Fick, J., Gunnarsson, L., Larsson, D.G.J.,  
400 Sumpter, J.P., Tysklind, M., Ruden, C., 2015. Improving Environmental Risk Assessment of Human  
401 Pharmaceuticals. *Environmental Science & Technology* 49, 5336-5345.
- 402 Amos, G.C.A., Gozzard, E., Carter, C.E., Mead, A., Bowes, M.J., Hawkey, P.M., Zhang, L.H., Singer, A.C., Gaze,  
403 W.H., Wellington, E.M.H., 2015. Validated predictive modelling of the environmental resistome. *Isme Journal*  
404 9, 1467-1476.
- 405 Besse, J.P., Garric, J., 2008. Human pharmaceuticals in surface waters implementation of a prioritization  
406 methodology and application to the French situation. *Toxicology Letters* 176, 104-123.
- 407 Burchall, J.J., 1973. Mechanism of action of trimethoprim-sulfamethoxazole. II. *Journal of Infectious Diseases*  
408 128, S437-S441.
- 409 Christensen, A.M., Markussen, B., Baun, A., Halling-Sørensen, B., 2009. Probabilistic environmental risk  
410 characterization of pharmaceuticals in sewage treatment plant discharges. *Chemosphere* 77, 351-358.
- 411 Clara, M., Strenn, B., Kreuzinger, N., 2004. Carbamazepine as a possible anthropogenic marker in the aquatic  
412 environment: investigations on the behaviour of Carbamazepine in wastewater treatment and during  
413 groundwater infiltration. *Water Research* 38, 947-954.
- 414 Cooper, E.R., Siewicki, T.C., Phillips, K., 2008. Preliminary risk assessment database and risk ranking of  
415 pharmaceuticals in the environment. *Science of the Total Environment* 398, 26-33.
- 416 Coutu, S., Wyrsh, V., Wynn, H.K., Rossi, L., Barry, D.A., 2013. Temporal dynamics of antibiotics in  
417 wastewater treatment plant influent. *Science of the Total Environment* 458, 20-26.
- 418 Drlica, K., Zhao, X.L., 1997. DNA gyrase, topoisomerase IV, and the 4-quinolones. *Microbiology and*  
419 *Molecular Biology Reviews* 61, 377-+.
- 420 Gale, E.F., 1963. Mechanisms of antibiotic action. *Pharmacological reviews* 15, 481-530.
- 421 Gardner, M., Jones, V., Comber, S., Scrimshaw, M.D., Coello-Garcia, T., Cartmell, E., Lester, J., Ellor, B., 2013.  
422 Performance of UK wastewater treatment works with respect to trace contaminants. *Science of the Total*  
423 *Environment* 456, 359-369.
- 424 Golovko, O., Kumar, V., Fedorova, G., Randak, T., Grabic, R., 2014. Seasonal changes in antibiotics,  
425 antidepressants/psychiatric drugs, antihistamines and lipid regulators in a wastewater treatment plant.  
426 *Chemosphere* 111, 418-426.

427 Gracia-Lor, E., Sancho, J.V., Serrano, R., Hernandez, F., 2012. Occurrence and removal of pharmaceuticals in  
428 wastewater treatment plants at the Spanish Mediterranean area of Valencia. *Chemosphere* 87, 453-462.

429 Hooper, D.C., Wolfson, J.S., Ng, E.Y., Swartz, M.N., 1987. Mechanisms of action of resistance to ciprofloxacin  
430 *American Journal of Medicine* 82, 12-20.

431 Huerta, B., Marti, E., Gros, M., Lopez, P., Pompeo, M., Armengol, J., Barcelo, D., Balcazar, J.L., Rodriguez-  
432 Mozaz, S., Marce, R., 2013. Exploring the links between antibiotic occurrence, antibiotic resistance, and  
433 bacterial communities in water supply reservoirs. *Science of the Total Environment* 456, 161-170.

434 Johnson, A.C., 2010. Natural Variations in Flow Are Critical in Determining Concentrations of Point Source  
435 Contaminants in Rivers: An Estrogen Example. *Environmental Science & Technology* 44, 7865-7870.

436 Johnson, A.C., Keller, V., Dumont, E., Sumpter, J.P., 2015. Assessing the concentrations and risks of toxicity  
437 from the antibiotics ciprofloxacin, sulfamethoxazole, trimethoprim and erythromycin in European rivers.  
438 *Science of the Total Environment* 511, 747-755.

439 Johnson, A.C., Tanaka, H., Okayasu, Y., Suzuki, Y., 2007. Estrogen content and relative performance of  
440 Japanese and British sewage treatment plants and their potential impact on endocrine disruption.  
441 *Environmental Sciences* 14, 319-329.

442 Kasprzyk-Hordern, B., Dinsdale, R.M., Guwy, A.J., 2009. The removal of pharmaceuticals, personal care  
443 products, endocrine disruptors and illicit drugs during wastewater treatment and its impact on the quality of  
444 receiving waters. *Water Research* 43, 363-380.

445 Kosma, C.I., Lambropoulou, D.A., Albanis, T.A., 2014. Investigation of PPCPs in wastewater treatment plants  
446 in Greece: Occurrence, removal and environmental risk assessment. *Science of the Total Environment* 466,  
447 421-438.

448 Kuroda, K., Nakada, N., Hanamoto, S., Inaba, M., Katayama, H., Do, A.T., Nga, T.T.V., Oguma, K., Hayashi, T.,  
449 Takizawa, S., 2015. Pepper mild mottle virus as an indicator and a tracer of fecal pollution in water  
450 environments: Comparative evaluation with wastewater-tracer pharmaceuticals in Hanoi, Vietnam. *Science*  
451 *of the Total Environment* 506, 287-298.

452 Marti, E., Jofre, J., Balcazar, J.L., 2013. Prevalence of Antibiotic Resistance Genes and Bacterial Community  
453 Composition in a River Influenced by a Wastewater Treatment Plant. *Plos One* 8.

454 Marti, E., Variatza, E., Balcazar, J.L., 2014. The role of aquatic ecosystems as reservoirs of antibiotic  
455 resistance. *Trends in Microbiology* 22, 36-41.

456 McArdell, C.S., Molnar, E., Suter, M.J.F., Giger, W., 2003. Occurrence and fate of macrolide antibiotics in  
457 wastewater treatment plants and in the Glatt Valley Watershed, Switzerland. *Environmental Science &*  
458 *Technology* 37, 5479-5486.

459 Nakada, N., Kiri, K., Shinohara, H., Harada, A., Kuroda, K., Takizawa, S., Takada, H., 2008. Evaluation of  
460 pharmaceuticals and personal care products as water-soluble molecular markers of sewage. *Environmental*  
461 *Science & Technology* 42, 6347-6353.

462 Narumiya, M., Nakada, N., Yamashita, N., Tanaka, H., 2013. Phase distribution and removal of  
463 pharmaceuticals and personal care products during anaerobic sludge digestion. *Journal of Hazardous*  
464 *Materials* 260, 305-312.

465 Ort, C., Lawrence, M.G., Rieckermann, J., Joss, A., 2010. Sampling for Pharmaceuticals and Personal Care  
466 Products (PPCPs) and Illicit Drugs in Wastewater Systems: Are Your Conclusions Valid? A Critical Review.  
467 *Environmental Science & Technology* 44, 6024-6035.

468 Pereira, A.M.P.T., Silva, L.J.G., Meisel, L.M., Lino, C.M., Pena, A., 2015. Environmental impact of  
469 pharmaceuticals from Portuguese wastewaters: geographical and seasonal occurrence, removal and risk  
470 assessment. *Environmental Research* 136, 108-119.

471 Piscitelli, S.C., Danziger, L.H., Rodvold, K.A., 1992. Clarithromycin and azithromycin - new macrolide  
472 antibiotics. *Clinical Pharmacy* 11, 137-152.

473 Retsema, J., Girard, A., Schelkly, W., Manousos, M., Anderson, M., Bright, G., Borovoy, R., Brennan, L.,  
474 Mason, R., 1987. Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring  
475 macrolide with improved potency against gram-negative organisms. *Antimicrobial Agents and*  
476 *Chemotherapy* 31, 1939-1947.

477 Rodriguez-Mozaz, S., Chamorro, S., Marti, E., Huerta, B., Gros, M., Sanchez-Melsio, A., Borrego, C.M.,  
478 Barcelo, D., Balcazar, J.L., 2015. Occurrence of antibiotics and antibiotic resistance genes in hospital and  
479 urban wastewaters and their impact on the receiving river. *Water Research* 69, 234-242.

480 Seydel, J.K., Wempe, E., Miller, G.H., Miller, L., 1972. Kinetics and mechanisms of action of trimethoprim and  
481 sulfonamides, alone or in combination, upon *Escherichia coli*. *Chemotherapy* 17, 217-237.

482 Singer, A.C., Jarhult, J.D., Grabic, R., Khan, G.A., Lindberg, R.H., Fedorova, G., Fick, J., Bowes, M.J., Olsen, B.,  
483 Soderstrom, H., 2014. Intra- and Inter-Pandemic Variations of Antiviral, Antibiotics and Decongestants in  
484 Wastewater Treatment Plants and Receiving Rivers. *Plos One* 9, 14.

485 Sui, Q., Huang, J., Deng, S.B., Chen, W.W., Yu, G., 2011. Seasonal Variation in the Occurrence and Removal of  
486 Pharmaceuticals and Personal Care Products in Different Biological Wastewater Treatment Processes.  
487 *Environmental Science & Technology* 45, 3341-3348.

488 Williams, R.J., Keller, V.D.J., Johnson, A.C., Young, A.R., Holmes, M.G.R., Wells, C., Gross-Sorokin, M.,  
489 Benstead, R., 2009. A national risk assessment for intersex in fish arising from steroid estrogens.  
490 *Environmental Toxicology and Chemistry* 28, 220-230.

491 Zhang, H., Du, M.M., Jiang, H.Y., Zhang, D.D., Lin, L.F., Yea, H., Zhang, X., 2015. Occurrence, seasonal  
492 variation and removal efficiency of antibiotics and their metabolites in wastewater treatment plants,  
493 Jiulongjiang River Basin, South China. *Environmental Science-Processes & Impacts* 17, 225-234.